{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:13:01Z","timestamp":1767150781010,"version":"build-2238731810"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ygyno.2016.05.015","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T15:29:32Z","timestamp":1464017372000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center"],"prefix":"10.1016","volume":"142","author":[{"given":"Brooke A.","family":"Schlappe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.05.015_bb0005","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0020","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0025","author":"Institute NC"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0030","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2014.00043","article-title":"Diffusion of intraperitoneal chemotherapy in women with advanced ovarian cancer in community settings 2003\u20132008: the effect of the NCI clinical recommendation","volume":"4","author":"Bowles","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2014.06.011","article-title":"Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer","volume":"134","author":"Fairfield","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2015.07.094","article-title":"Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center","volume":"138","author":"Liang","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0050","series-title":"The New York Times","article-title":"Effective ovarian cancer treatment is underused, study finds","author":"Grady","year":"2015"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1634\/theoncologist.2007-0224","article-title":"Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view","volume":"13","author":"Vergote","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/IGC.0b013e3181c7f670","article-title":"Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer","volume":"20","author":"Robinson","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2009.04.001","article-title":"Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer","volume":"114","author":"Naumann","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0075","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2011.36.1352","article-title":"Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II\/III epithelial ovarian cancer","volume":"29","author":"Konner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0080","author":"Institute NC"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157488707781662698","article-title":"Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions","volume":"2","author":"Markman","year":"2007","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0090","first-page":"2803","article-title":"Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer","volume":"29","author":"Zeimet","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0095","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00404-015-3709-y","article-title":"Growth factors, silver dressing and negative pressure wound therapy in the management of hard-to-heal postoperative wounds in obstetrics and gynecology: a review","volume":"292","author":"Stanirowski","year":"2015","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/IGC.0000000000000315","article-title":"Benefit of negative pressure drain within surgical wound after cytoreductive surgery for ovarian cancer","volume":"25","author":"Kim","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2014.09.013","article-title":"Intensive postoperative glucose control reduces the surgical site infection rates in gynecologic oncology patients","volume":"136","author":"Al-Niaimi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2014.06.012","article-title":"A phase II trial of a surgical protocol to decrease the incidence of wound complications in obese gynecologic oncology patients","volume":"134","author":"Novetsky","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.amjsurg.2012.06.007","article-title":"Prevention of surgical site infections in high-risk patients with laparotomy incisions using negative-pressure therapy","volume":"205","author":"Blackham","year":"2013","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0b013e3182501bae","article-title":"Negative pressure wound therapy for at-risk surgical closures in patients with multiple comorbidities: a prospective randomized controlled study","volume":"255","author":"Masden","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0135","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1471-0528.2011.03179.x","article-title":"Ports and complications for intraperitoneal chemotherapy delivery","volume":"119","author":"Helm","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jgo.2012.02.007","article-title":"Intraperitoneal chemotherapy in older women with epithelial ovarian cancer","volume":"3","author":"O'Cearbhaill","year":"2012","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0145","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.2014.60.2797","article-title":"Intraperitoneal chemotherapy: long-term outcomes revive a long-running debate","volume":"33","author":"Bookman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/IGC.0000000000000389","article-title":"Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer","volume":"25","author":"Suidan","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0155","series-title":"47th Annual Meeting of the Society of Gynecologic Oncology","article-title":"A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG oncology study","year":"2016"},{"key":"10.1016\/j.ygyno.2016.05.015_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.05.015_bb0175","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2016.07.097","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581630734X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581630734X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T17:21:43Z","timestamp":1536686503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581630734X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S009082581630734X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}